CD33 and acute myeloid leukemia: The phase 1 dose escalation trial evaluating CD33 × CD3 BiTE (AMG330) has registered a cCR rate of 19% in R/R AML patients [85], indicating the need to investigate potential combinatorial approaches with other drugs to achieve a more effective and durable response in this setting.